ESR1 and breast carcinoma: Besides, triple negative breast cancer (TNBC) represents a specific subtype accounting for approximately 15–20% of breast cancers, which is clinically negative for the expression of ER and PR, and lacks HER2 overexpression (ER-, PR-, HER2-).